

* 馮思中醫師

所有發表期刊論文

Publication: (* correspondence; *co-1st author)

1. **Pang ST**, Chuang CK, Ho WP, Chu SH: Pseudotumor formation in the bladder as a late complication of total hip replacement. **J Urology**, 1997 June 157:2254.
2. Liu KL, Chen CS, **Pang ST**, Chu SH: Management of Fournier's gangrene—experience with 57 patients. **J. Uro. R. O. C.**, 1998 Sept. 9:121–125.
3. Chu SH, **Pang ST**, YJ Chiang, Chuang CK, Chen HW, Chen CS, Chou CC, Huang CC: Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral. **Transplant Proc.** 1998 Nov;30(7):3521–3.
4. **Pang ST**, Wu MS, Yu HM, Chiang YJ, Chu SH, Chen WH, Vandewalle A.: University of Wisconsin preservation solution enhances intrarenal nitric oxide production. **Transplant Proc.** 2000 Nov;32(7):1617–8.
5. Dillner K, Kindblom J, Flores-Morales A, **Pang ST**, Tornell J, Wennbo H, Norstedt G.: Molecular characterization of prostate hyperplasia in prolactin-transgenic mice by using cDNA representational difference analysis. **Prostate.** 2002 Jul 1;52(2):139–49.
6. **Pang ST**, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A.: Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. **Endocrinology.** 2002 Dec;143(12):4897–906.
7. Weng WH, Ahlen J, Lui WO, Brosjo O, **Pang ST**, Von Rosen A, Auer G, Larsson O, Larsson C: Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis. **Br J Cancer.** 2003 Aug 18;89(4):720–6.
8. Wu X, **Pang ST**, Sahlin L, Blanck A, Norstedt G, Flores-Morales A.: Gene Expression Profiling of the Effects of Castration and Estrogen Treatment in the Rat Uterus. **Biol Reprod.** 2003 Oct;69(4):1308–17.
9. **Pang ST**: A functional genomics approach to study prostatic disorders. Thesis. 2003 Karolinska Institute, Sweden. ISBN 91-7349-640-5
10. **Pang ST**, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. **Oncol Rep.** 2004 Jun;11(6):1187–92.
11. **Pang ST**, Fang XL, Valdman A, Norstedt G, Pousette A, Egevad L and Ekman P: Expression of ezrin in prostatic intraepithelial neoplasia. **Urology.** 2004 Mar;63(3):609–12.
12. Weng WH, Wejde J, Ahlen J, **Pang ST**, Lui WO, Larsson C: Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative genomic hybridization (CGH), and array CGH. **Cancer Genet Cytogenet.** 2004 Apr 1;150(1):27–32.
13. Valdman A, Fang XL, **Pang ST**, Ekman P, Egevad L: PIM-1 Expression in Prostatic Intraepithelial Neoplasia and Human Prostate Cancer. **Prostate.** 2004 Sep 1;60(4):367–71.
14. Weng WH, Lerner M, Grander D, Ahlen J, Villablanca A, **Pang ST**, Wejde J, Lui WO, Larsson C: Loss of chromosome 13q is a frequently acquired event in genetic progression of soft tissue sarcomas in the abdominal cavity. **Int J Oncol.** 2005 Jan;26(1):5–16.

15. Chang CT, Weng WH, Chou AS, Chuang CK, Porwit-McDonald A, **Pang ST**, Larsson C, Liao SK : Immunophenotypic and molecular cytogenetic features of the cell line UP-LN1 established from a lymph node metastasis of a poorly-differentiated carcinoma. **Anticancer Res.** 2005 Mar-Apr; 25(2A):683-91.
16. Chuan Y, **Pang ST**, Bergh A, Norstedt G, Pousette A : Androgens induce CD-9 in human prostate tissue. **Int J Androl.** 2005 Oct;28(5):291-6.
17. Valdman A, Fang X, **Pang ST**, Nilsson B, Ekman P, Egevad L : Ezrin Expression in Prostate Cancer and Benign Prostatic Tissue. **European Urology.** 2005 Nov;48(5):852-7.
18. **Pang ST**, Weng WH, Flores-Morales A, Johansson B, Pourian MR, Nilsson P, Pousette A, Larsson C, Norstedt G. : Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. **Prostate.** 2006 Feb 1;66(2):157-72.
19. Wu CF, Chang PL, Chen CH, Chuang CK, Weng HH and **Pang ST***: The outcome of dialysis patients with upper urinary tract transitional cell carcinoma. **Journal of Urology,** 2006 Aug;176(2):477-81.
20. Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, **Pang ST**, Norstedt G, Bergman T, Pousette A. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. **Prostate.** 2006 Sep 1;66(12):1235-44.
21. Chuan YC, **Pang ST**, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. **J Biol Chem.** 2006 Oct 6;281(40):29938-48.
22. Ni J, **Pang ST**, Yeh S. : Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. **Prostate.** 2007 Apr 1;67(5):463-71.
23. Wu CF, **Pang ST**, Chen CS, Chuang CK, Chen Y, Lin PY. : The impact factors on prognosis of patients with pT3 upper urinary tract transitional cell carcinoma. **J Urol.** 2007 Aug;178(2):446-50.
24. Yang CH, Lin WC, Chuang CK, Chang YC, **Pang ST**, Lin YC, Kuo TT, Hsieh JJ, Chang JW. : Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. **Br J Dermatol.** 2008 Mar;158(3):592-6.
25. **Pang ST**, Chao A, Wang CJ, Lin G, Lee CL. : Transurethral partial cystectomy and laparoscopic reconstruction for the management of bladder endometriosis. **Fertil Steril.** 2008 Nov;90(5):2014. e1-3.
26. Yeh CN, **Pang ST**, Wu RC, Chen TW, Jan YY, Chen MF. : Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. **Oncol Rep.** 2009 Jan;21(1):49-56.
27. Lee MS, Sun MT, **Pang ST**, Ueng SWN, Chen SC, Hwang TL, Wang TH. Evaluation of differentially expressed genes by shear stress in human osteoarthritic chondrocytes in vitro. **Chang Gung Med J.** 2009 Jan-Feb;32(1):42-50.
28. Wang LJ*, Wong YC, Chuang CK, Huang CC, **Pang ST**. : Diagnostic Accuracy of Transitional Cell Carcinoma on Multi-detector Computed Tomography Urography in Patients with Gross Hematuria. **J Urol.** 2009 Feb;181(2):524-31.
29. Ni J, Mai T, **Pang ST**, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S. : In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer. **Clin Cancer Res.** 2009 Feb 1;15(3):898-906.

30. Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, **Pang ST**, Hasumi K, Ferrone S, Liao SK. : Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta(2)-microglobulin genes. **Cancer Immunol Immunother.** 2009 Mar;**58**(3):395-408.
31. **Pang ST**, Hsieh WC, Chuang CK, Chao CH, Weng WH, Juang HH. : Thioredoxin-interacting protein: an oxidative-stress related gene is upregulated by glucose in human prostate carcinoma cells. **J Molecular Endocrinology** 2009 Mar;**42**(3):205-14.
32. Yeh CN, **Pang ST***, Chen TW, Wu RC, Weng WH, Chen MF. : Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma. **BMC Cancer.** 2009 Jul **15**;9(1):233. (co-first author)
33. Hou MM, Chang JW, **Pang ST**, Chiang YJ, Shen YC, Liao SK, Hsieh JJ, Yeh KY, Chang NJ, Chuang CK. : Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma. **Chang Gung Med J.** 2010 Jan-Feb;**33**(1):25-35.
34. Chuang KL, Chuang HC, Ng KF, Chang YH, Wu CT, Chuang CK, Liao SK, **Pang ST***. : Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients. **BJU Int.** 2010 May;**105**(10):1413-6.
35. Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, **Pang ST**, Norstedt G, Pousette A, Flores-Morales A. : Ezrin mediates c-Myc actions in prostate cancer cell invasion. **Oncogene.** 2010 Mar **11**;29(10):1531-42.
36. Chuang KL, Liaw CC, Ueng SH, Liao SK, **Pang ST**, Chang YH, Chuang HC, Chuang CK. : Mixed germ cell tumor metastatic to the skin: Case report and literature review. **World J Surg Oncol.** 2010 Mar **23**;8(1):21.
37. Lin KJ, **Pang ST***, Chang YH, Wu CT, Chuang KL, Chuang HC, Chuang CK. : Age-related reference ranges of serum prostate-specific antigen among Taiwanese men without clinical evidence of prostate cancer. **Chang Gung Medical Journal.** 2010 Mar-Apr;**33**(2):182-7.
38. Chang YH, Chuang CK, **Pang ST**, Wu CT, Chuang KL, Liao SK. : The impact of regular biopsy in the first cystoscopic follow-up and other predictors on the recurrence of superficial bladder tumors. **Chang Gung Med J.** 2010 Mar-Apr;**33**(2):174-87.
39. Wu CF, Ng KF, Chen CS, Chang PL, Chuang CK, Weng WH, Liao SK, **Pang ST***. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. **Br J Cancer.** 2010 Sep **7**;103(6):852-60.
40. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, Chang YH, Chuang HC, **Pang ST**, * : Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. **Biomaterials.** 2010 Oct;**31**(28):7355-63.
41. Wu CF, **Pang ST**, Shee JJ, Chang PL, Chuang CK, Chen CS, Liao SK, Weng WH. Identification of genetic alterations in upper urinary tract urothelial carcinoma in end-stage renal disease patients. **Genes Chromosomes Cancer.** 2010 Oct;**49**(10):928-34
42. Yeh CN, **Pang ST**, Jung SM, Chen TW, Jan YY, Chen MF. Cytoplasmic overexpression with membrane accentuation of stratifin in intrahepatic mass-forming cholangiocarcinoma after hepatectomy: correlation with clinicopathologic features and patient survival. **J Surg Oncol.** 2010 Nov **1**;102(6):608-14.

43. Chuang KL, Pang ST, Liao SK, Wu CT, Chang YH, Chuang HC, Chuang CK. Epstein-Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas. **BJU Int.** 2011 Jan;107(1):150-4.
44. Chang YH, Chuang CK, Pang ST, Wu CT, Chuang KL, Chuang HC, Liao SK. Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma. **Kaohsiung J Med Sci.** 2011 Feb;27(2):59-63.
45. Zhang Z, Pang ST, Kasper KA, Luan C, Wondergem B, Lin F, Chuang CK, Teh BT, Yang XJ. FXYD3: A Promising Biomarker for Urothelial Carcinoma. **Biomark Insights.** 2011 Feb 15;6:17-26
46. Chen HC, Chou AS, Liu YC, Hsieh CH, Kang CC, Pang ST, Yeh CT, Liu HP, Liao SK. Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN- γ . **Lab Invest.** 2011 Oct;91(10):1502-13.
47. Liu JM, Chuang CK, Chang YH, Ng KF, Wang LJ, Chuang KL, Chuang HC, Pang ST*. A simple renal cyst invaded by infiltrating urothelial carcinoma mimicking a Bosniak Class IV renal cyst. **Clin Nephrol.** 2011 Nov;76(5):412-6.
48. Luo CC, Ming YC, Chao HC, Chu SM, Pang ST*. Heparin-Binding Epidermal Growth Factor-Like Growth Factor Downregulates Expression of Activator Protein-1 Transcription Factor after Intestinal Ischemia-Reperfusion Injury. **Neonatology.** 2011 Nov 9;99(4):241-246.
49. Hua MY, Yang HW, Liu HL, Tsai RY, Pang ST, Chuang KL, Chang YS, Hwang TL, Chang YH, Chuang HC, Chuang CK. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. **Biomaterials.** 2011 Dec;32(34):8999-9010.
50. Wu CC, Liu FK, Lin LH, Pang ST, Chuang CK, Pan TM, Ou KL, Ko FH. Surface cleaning of the nanowire field-effect transistor for gene detection. **J Nanosci Nanotechnol.** 2011 Dec;11(12):10639-43.
51. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C. ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors. **Neoplasia.** 2012 Jan;14(1):74-83.
52. Yang HW, Hua MY, Liu HL, Tsai RY, Chuang CK, Chu PC, Wu PY, Chang YH, Chuang HC, Yu KJ, Pang ST*. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy. **ACS Nano.** 2012 Feb 28;6(2):1795-805.
53. Fan KH, Chen YC, Leung WM, Chuang CK, Pang ST, Hong JH. Adjuvant and salvage radiotherapy for urothelial cell carcinoma of the upper urinary tract: experience in a single institution. **Chang Gung Med J.** 2012 May;35(3):247-54
54. Yang HW, Hua MY, Liu HL, Tsai RY, Pang ST, Hsu PH, Tang HJ, Yen TC, Chuang CK. An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer. **Biomaterials.** 2012 May;33(15):3919-30.
55. Huang WK, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, Wang HM, Lin YC, Hsieh JJ, Ou LY, Tsai SI, Yang CH, Yang CT, Chang JW. Everolimus in metastatic renal cell carcinoma: preliminary experience from chang gung memorial hospital. **Chang Gung Med J.** 2012 Sep;35(5):402-7.
56. Lai MW, Chen TC, Pang ST, Yeh CT. Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. **Urol Oncol.** 2012 Nov-Dec;30(6):871-8.

57. Chou YT, Hsieh CH, Chiou SH, Hsu CF, Kao YR, Lee CC, Chung CH, Wang YH, Hsu HS, **Pang ST**, Shieh YS, Wu CW. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. **Cell Death Differ.** 2012 Dec;19(12):2015-28.
58. Yu HP, **Pang ST***, Chaudry IH. Hepatic Gene Expression Patterns Following Trauma-Hemorrhage: Effect of Post-Treatment with Estrogen. **Shock.** 2013 Jan;39(1):77-82.
59. Wu CE, Lin YC, Hong JH, Chuang CK, **Pang ST**, Liaw CC. Prognostic Value of Complete Response in Patients with Muscle-invasive Bladder Cancer Undergoing Concurrent Chemoradiotherapy. **Anticancer Res.** 2013 Jun;33(6):2605-10.
60. Yeh CN, Weng WH, Lenka G, Tsao LC, Chiang KC, **Pang ST**, Chen TW, Jan YY, Chen MF. cDNA microarray profiling of rat cholangiocarcinoma induced by thioacetamide. **Mol Med Rep.** 2013 Aug;8(2):350-60.
61. Huang YW, Wu CS, Chuang CK, **Pang ST**, Pan TM, Yang YS, Ko FH. Real-Time and Label-Free Detection of the Prostate-Specific Antigen in Human Serum by a Polycrystalline Silicon Nanowire Field-Effect Transistor Biosensor. **Anal Chem.** 2013 Aug 20;85(16):7912-8.
62. Poon SL, **Pang ST***, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT. Genome-wide mutational signatures of aristolochic Acid and its application as a screening tool. **Sci Transl Med.** 2013 Aug 7;5(197):197ra101.
63. Hsieh CH, Chen HC, Chang YH, **Pang ST**, Kuo ML, Chuang CK, Liao SK. Co-existence of Epithelioid and Fibroblastoid Subsets in a Sarcomatoid Renal Carcinoma Cell Line Revealed by Clonal Studies. **Anticancer Res.** 2013 Nov;33(11):4875-89.
64. Lenka G, Weng WH, Chuang CK, Ng KF, **Pang ST***. Aberrant expression of the PRAC gene in prostate cancer. **Int J Oncol.** 2013 Dec;43(6):1960-6.
65. Hsu I, Chuang KL, Slavin S, da J, Lim WX, **Pang ST**, O'Brien JH, Yeh S. Suppression of ER β signaling via ER β knockout or ER β antagonist protects against bladder cancer development. **Carcinogenesis.** 2014 Mar;35(3):651-61.
66. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, **Pang ST**, Bjartell A, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. **Nucleic Acids Res.** 2014 Jan 1;42(2):999-1015.
67. Ye D, Eto M, Chung JS, Kimura G, Chang WC, Chang YH, **Pang ST**, Lee JL, Niu Y, Gurney H, Uemura H. Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia. **Clin Genitourin Cancer.** 2014 Aug;12(4):225-33.
68. Yang HW, Lin CW, Hua MY, Liao SS, Chen YT, Chen HC, Weng WH, Chuang CK, **Pang ST***, Ma CC. Combined Detection of Cancer Cells and a Tumor Biomarker using an Immunomagnetic Sensor for the Improvement of Prostate-Cancer Diagnosis. **Adv Mater.** 2014 Jun;26(22):3662-6.
69. Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, Ting HJ, **Pang ST**, Yeh SD, Ma WL, Chen CJ, Wu WG, Chang C. Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress

- wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. **Mol Oncol.** 2014 Dec;8(8):1575–1587.
70. Chang NJ, Weng WH, Chang KH, Liu EK, Chuang CK, Luo CC, Lin CH, Wei FC, **Pang ST**. Genome-wide gene expression profiling of ischemia-reperfusion injury in rat kidney, intestine and skeletal muscle implicate a common involvement of MAPK signaling pathway. **Mol Med Rep.** 2015 May;11(5):3786–93.
71. Pan TM, Wang CW, Huang YS, Weng WH. **Pang ST**. Effect of Postdeposition Annealing on the Structural and Sensing Characteristics of Tb₂O₃ and Tb,Ti₂O₇ Sensing Films for Electrolyte-Insulator-Semiconductor pH Sensors. **Journal of The Electrochemical Society**, 162 (4) B83–B88 (2015).
72. Liu FC, **Pang ST**, Tsai YF, Chaudry IH, Yu HP. Hepatoprotective Effect of Casodex Following Trauma-Hemorrhage in a Rodent Model. **Shock.** 2015 May;43(5):470–4.
73. Huang YC, Chen MF, Shi CS, Shindel AW, Huang CE, **Pang ST**, Chuang CK, Chen CS, Chang YH, Lin WY, Ho DR, Chin CC, Kuo YH, Wu CF. The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. **J Urol.** 2015 Mar 18. pii: S0022-5347(15)03374-1.
74. **Song Ling Poon**, **Mi Ni Huang**, **Yang Choo**, **John R McPherson**, **Willie Yu**, **Hong Lee Heng**, **Anna Gan**, **Swe Swe Myint**, **Ee Yan Siew**, **Lian Dee Ler**, **Lay Guat Ng**, **Wen-Hui Weng**, **Cheng-Keng Chuang**, **John SP Yuen**, **See-Tong Pang**, **Patrick Tan**, **Bin Tean Teh**, **Steven G Rozen**. Mutation signatures implicate aristolochic acid in bladder cancer development. **Genome Med.** 2015 Apr 28;7(1):38.
75. Song W, Yeh CR, He D, Wang Y, Xie H, **Pang ST**, Chang LS, Li L, Yeh S. Infiltrating neutrophils promote renal cell carcinoma progression via VEGF α /HIF2 α and estrogen receptor β . **Oncotarget.** 2015 Aug 7;6(22):19290–304.
76. Lu SH, Tsai WS, Chang YH, Chou TY, **Pang ST**, Lin PH, Tsai CM, Chang YC. Identifying Cancer Origin Using Circulating Tumor Cells. **Cancer Biol Ther.** 2016 Apr 2;17(4):430–8
77. **Weng WH**, Chen YT, Yu KJ, Chang YH, Chuang CK, **Pang ST**. Genetic alterations of HER genes in chromophobe renal cell carcinoma. **Oncol Lett.** 2016 Mar;11(3):2111–2116.
78. Shao IH, Chang YH, Yu KJ, Lin PH, Liu CY, Chuang CK, **Pang ST**. Outcomes and prognostic factors of simple partial cystectomy for localized bladder urothelial cell carcinoma. **Kaohsiung J Med Sci.** 2016 Apr;32(4):191–5.
79. Liu JM, Lin PH, Hsu RJ, Chang YH, Cheng KC, **Pang ST**, Lin SK. Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer. **Medicine (Baltimore).** 2016 Aug;95(31):e4475.
80. **Pang ST**, F.W. Lin, C.K. Chung, H.W. Yang. Co-delivery of docetaxel and p44/42 MAPK siRNA using PSMA antibody-conjugate BSA-PEI layer-by-layer nanoparticles for prostate cancer target therapy. **Macromolecular Bioscience.** 2017 Jan 27.
81. Hsieh CH, Hsiung SC, Yeh CT, Yen CF, Chou YW, Lei WY, **Pang ST**, Chuang CK, Liao SK. **Differential expression of CD44 and CD24 markers discriminates the epithelioid from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells.** **Oncotarget.** 2017 Jan 21.
82. Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, Myint SS, Loh JL, Ong P, Sam XX, Huang D, Lim T, Tan PH, Nagarajan S, Cheng CW, Ho H, Ng LG, Yuen J, Lin PH, Chuang CK, Chang

- YH, Weng WH, Rozen SG, Tan P, Creasy CL, [Pang ST](#), McCabe MT, Poon SL, Teh BT. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. *Sci Transl Med*. 2017 Feb 22;9(378).
83. Lin SK, Liu JM, Chang YH, Ting YT, [Pang ST](#), Hsu RJ, Lin PH. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study. *Ther Clin Risk Manag*. 2017 Feb 23;13:245-253.
84. Liu JM, Chang YH, Ho TW, Chang FW, Pang ST, Hsu RJ, Lin PH. Patients with Epididymo-Orchitis and Meteorological Impact in Taiwan: A Nationwide Population-Based Study. *Can J Infect Dis Med Microbiol*. 2017;2017:1506857
85. Chuang CK, Lin HCA, Tasi HY, Lee KH, Kao Y, Chuang FL, Chang YH, Lin PH, Liu CY, [Pang ST](#). Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma. *Int Urol Nephrol*. 2017 May 25. doi: 10.1007/s11255-017-1629-4.
86. Hsu CL, Liu JS, Lin TW, Chang YH, Kuo YC, Lin AC, Ting HJ, [Pang ST](#), Lee LY, Ma WL, Lin CC, Wu WG. Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. *Oncotarget*. 2017 May 13. doi: 10.18632/oncotarget.17843.